Hans Hammers
Overview
Explore the profile of Hans Hammers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
2876
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wanniarachchi H, Schuetze R, Deng Y, Hamal K, Pavlich C, Tankoano P, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075618
There has been much progress in treating kidney cancer, with several new drugs being approved over the last few years [...].
2.
Hugaboom M, Wirth L, Street K, Ruthen N, Jegede O, Schindler N, et al.
Cancer Discov
. 2025 Feb;
PMID: 39992403
Immune checkpoint inhibitors (ICI) targeting the PD-1 pathway have transformed treatment of advanced renal cell carcinoma (RCC), but mechanisms underlying therapeutic response remain largely unknown. Herein, we perform transcriptomic analysis...
3.
Khene Z, Bhanvadia R, Tachibana I, Issa W, Graber W, Trevino I, et al.
Clin Genitourin Cancer
. 2025 Feb;
23(2):102307.
PMID: 39923263
Introduction: The impact of neoadjuvant immune checkpoint inhibitors (ICIs) on perioperative outcomes of radical nephrectomy (RN) with inferior vena cava (IVC) thrombectomy for renal cell carcinoma (RCC) remains unclear. This...
4.
Bex A, Jewett M, Lewis B, Abel E, Albiges L, Berg S, et al.
Eur Urol
. 2025 Jan;
PMID: 39855942
Neoadjuvant systemic treatment strategies have improved outcomes in several solid tumour types. This success has not yet been replicated in renal cell carcinoma (RCC). A consensus and international collaboration are...
5.
Thapa P, Debnath S, Bedi A, Parashar M, Gonzalez P, Reus J, et al.
Cancers (Basel)
. 2025 Jan;
16(24).
PMID: 39766079
: Fibroblast activation protein (FAP)-targeted theranostic radiopharmaceuticals have shown desired tumor-to-background organ selectivity due to the ubiquitous presence of FAP within the tumor microenvironment. However, suboptimal tumor retention and fast...
6.
Choueiri T, Albiges L, Barthelemy P, Iacovelli R, Emambux S, Molina-Cerrillo J, et al.
Lancet
. 2024 Sep;
404(10460):1309-1320.
PMID: 39284329
Background: Immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor tyrosine kinase inhibitors are cornerstones of first-line treatment for advanced renal cell carcinoma; however, optimal treatment sequencing after progression...
7.
Gunenc D, Issa W, Gerald T, Zhou Q, Zhang S, Ibezue I, et al.
Clin Genitourin Cancer
. 2024 Sep;
22(5):102177.
PMID: 39218752
Background: Immunotherapy (IO) has improved outcomes for patients with metastatic renal cell carcinoma (mRCC). However, the timing of surgical intervention for cytoreductive nephrectomy (CN) is still controversial for this group...
8.
Choueiri T, Tomczak P, Park S, Venugopal B, Ferguson T, Symeonides S, et al.
N Engl J Med
. 2024 Apr;
390(15):1359-1371.
PMID: 38631003
Background: Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results regarding overall...
9.
Atkins M, Jegede O, Haas N, Mcdermott D, Bilen M, Stein M, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38604810
Background: As part of a partitioned survival analysis, treatment-free survival (TFS) can characterize the overall survival time patients spend between the cessation of immunotherapy and the start of subsequent therapy;...
10.
Choueiri T, Pal S, Lewis B, Poteat S, Pels K, Hammers H
Oncologist
. 2023 Dec;
29(2):91-98.
PMID: 38048064
The 5th Kidney Cancer Research Summit was a hybrid event hosted in Boston, MA in July 2023. As in previous editions, the conference attracted a wide representation of global thought...